NCT03907098: Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

NCT03907098
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled central nervous system metastasis
https://ClinicalTrials.gov/show/NCT03907098

Comments are closed.

Up ↑